Ramucirumab is a targeted drug used for the treatment of a variety of cancers, and its price, domestic marketability and the specific cost of a course of treatment are the focus of attention of patients and their families. This article will explore these in detail to help readers better understand the relevant knowledge.

How much is Ramucirumab?

Knowing the price of Ramucirumab can help patients and families plan their financial expenses and choose the treatment that works best for them.

Eli Lilly Pharmaceuticals exports the Turkish version of the original drug

Eli Lilly and the United States produce Ramucirumab, which is 100mg*2 vials. This innovator is widely recognized for its high quality and efficacy.

Other versions with generics

There are currently no generic versions of Ramucirumab in the Chinese market, but as more manufacturers join the production ranks, there may be more affordable options in the future.

Knowing the price information of different manufacturers can help patients make the best choice within their budget, and the price is for reference only.

Is Ramucirumab marketed in China?

It is important to clarify whether Ramucirumab has been marketed in China for patients to obtain the drug. Understanding its listing status and medical insurance policies can guide subsequent drug purchase decisions.

Listings in China

Ramucirumab has been marketed in China and was approved by the National Medical Products Administration (NMPA) in March 2022. This allows Chinese patients to purchase the drug through formal channels.

Medicare policy

Although Ramucirumab has been marketed in China, it has not yet entered the Chinese medical insurance system, so patients need to purchase it at their own expense.

Understanding the marketing status and medical insurance policies of Ramucirumab in China can help patients rationalize their treatment plans and explore more payment options.

How much is a course of Ramucirumab?

Calculating the cost of a course of Ramucirumab can help patients and families better plan their financial expenses and prepare for long-term treatment.

Recommended dosage and cost calculation

According to clinical guidelines, the recommended dose of Ramucirumab is 8mg/kg every two weeks for 60minutes as an intravenous infusion. In a patient weighing 70kg, for example, 560 mg per infusion is required, which means that approximately 5.6 100 mg of Ramucirumabb are required.

Variables in actual use

During the actual treatment process, the patient's weight, disease progression, and the doctor's specific recommendations will affect the final dosage and cost. In addition, different sales channels can also cause price fluctuations.

By calculating the cost of a course of treatment in detail, patients can more accurately estimate the cost of treatment and adjust their financial planning according to their situation. At the same time, we can continue to monitor market dynamics and policy changes, and we can also identify more opportunities to save money.